Actively Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Led by Alentis Therapeutics AG · Updated on 2025-11-20
80
Participants Needed
49
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a new drug that might help protect and preserve kidney function in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a type of autoimmune disease where the body's own immune system attacks itself, and in the case of AAV the body attacks its own small blood vessels. There are many small blood vessels in the kidneys meaning the kidneys are commonly affected in AAV. The main questions it aims to answer are: * Is the new drug well tolerated and safe? * Can the new drug protect and preserve kidney functions when is added to standard therapy? Researchers will compare the following groups to see how the new drug is tolerated and what effect to preserve kidney tissue has: * Group A: Standard treatment + ALE.F02 low dose infusions * Group B: Standard treatment + ALE.F02 high dose infusions * Group C: Standard treatment + ALE.F02 maximum dose infusions * Group D: Standard treatment + placebo infusions (inactive substance) The Treatment period will consist of 24 weeks beginning on Day 1, during which time participants will receive 13 infusions of the study medicine, along with standard therapy for kidney inflammation due to AAV. During the treatment period, participants will have the following assessments: * A brief physical examination focusing on their skin any pre-existing medical conditions that you have. * Collection of blood and urine samples for routine safety tests and to assess renal function. * Collection of blood samples: * To measure the amount of study medicine in their blood. This is called pharmacokinetics (PK) and it is tested to see how study medicine enters, moves through, and exits the body. * To test for antidrug antibodies (ADA). To check if their body create antibodies against the study medicine, as this could reduce its effect. * To measure biomarkers. Biomarkers are specific compounds in the body (can be protein, hormones, or genetic molecules) that indicate normal or abnormal processes taking place in your body and may be a sign of an underlying condition or disease (for example glucose levels are used as biomarker in managing diabetes). They are used to see how well the body responds to a treatment for a disease or condition. * Collection of urine to measure urine markers of vasculitis/inflammation called biomarkers. * Urine pregnancy test. A urine pregnancy test is a quick medical test that can tell if a woman is pregnant or not by checking for a hormone which is produced during pregnancy, usually in the urine. * Chest High Resolution Computed Tomography (HRCT) scan to check whether they have vasculitis affecting their lungs. A CT scan uses special x-ray equipment to take detailed pictures of body tissues and organs to diagnose and monitor conditions in various parts of the body. For the CT scan, they will need to lie still on a table. At Week 24 a second lung CT scan will be performed for participants whose initial scan showed lung vasculitis to see whether your lung vasculitis is getting better or ongoing/worse.
CONDITIONS
Official Title
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients 18 years or older of any race or ethnicity with a Clinical Frailty Scale score less than 7 within 3 months before RPGN onset attributed to AAV
- Willing and able to comply with study requirements and provide informed consent
- Willing to have a kidney biopsy performed before study drug administration at Week 6 or have a historical biopsy within 45 days prior
- Newly diagnosed with RPGN within 45 days before starting study drug, with loss of kidney function (eGFR between 10 and 50 mL/min/1.73 m2) and history of proteinuria and/or hematuria associated with illness
- Suspected RPGN due to AAV at screening with positive ANCA test (anti-MPO or anti-PR3)
- Body weight of at least 30 kg
- Female participants must not be pregnant or breastfeeding and either use highly effective birth control during the study and for at least 30 days after last dose or be of non-childbearing potential
- Female participants must agree not to donate eggs for 6 months after last dose
- Male participants must agree to use contraception or abstinence during the study and for 90 days after last dose
- Male participants must agree to abstain from sperm donation during the study and for 90 days after last dose
You will not qualify if you...
- History of previous RPGN that has resolved or relapsed
- Positive test for anti-glomerular basement membrane antibodies
- Evidence of active or latent tuberculosis
- Chronic infections that could worsen with RPGN or its standard treatments
- Active hepatitis B, hepatitis C, or HIV infection
- Use of prohibited medications
- Prior standard therapy exceeding high-dose glucocorticoid limits or planned treatment with avacopan
- Poor venous access
- Participation in investigational drug or device studies within specified timeframes before study
- History of autoimmune skin disorders except those related to AAV
- Diagnosis of systemic lupus erythematosus-AAV overlap or eosinophilic granulomatosis with polyangiitis
- Uncontrolled serious diseases unrelated to RPGN or AAV
- Recent live vaccine within 30 days or other vaccines within 7 days before first dose except influenza or pneumococcal
- Employment or family relation to study staff
- Not recovered from major surgery complications
- Active or recent alcohol or substance abuse
- Recent cancer diagnosis except certain skin cancers
- Severe lung bleeding with low oxygen or needing ventilatory support
- Dialysis or plasma exchange within 7 days before screening
- Known allergy to study drug or its ingredients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 49 locations
1
Vseobecna fakultni nemocnice v Praze
Prague, Czechia, 128 08
Actively Recruiting
2
Institut klinicke a experimentalni mediciny
Prague, Czechia, 140 21
Actively Recruiting
3
Aalborg University Hospital
Aalborg, Denmark, 9000
Actively Recruiting
4
Aarhus University Hospital
Aarhus, Denmark, 8200
Actively Recruiting
5
Rigshospitalet
Copenhagen, Denmark, 56 2100
Actively Recruiting
6
Odense University Hospital
Odense, Denmark, 5000
Actively Recruiting
7
Centre Hospitalier Boulogne sur Mer
Boulogne-sur-Mer, Cedex, France, 62200
Actively Recruiting
8
CHU Bordeaux - Hopital Pellegrin
Bordeaux, France, 33000
Actively Recruiting
9
CHRU de Brest - Hopital de la Cavale Blanche
Brest, France, 29200
Actively Recruiting
10
CHU Grenoble-Alpes - Hopital Michallon
La Tronche, France, 38700
Actively Recruiting
11
CHU de Nantes - Hotel-Dieu
Nantes, France, 44000
Actively Recruiting
12
CHU de Nimes
Nîmes, France, 31000
Actively Recruiting
13
AP-HP Hopital Pitie-Salpetriere
Paris, France, 75013
Actively Recruiting
14
AP-HP Hopital Cochin
Paris, France, 75014
Actively Recruiting
15
CHU de Toulouse - Hopital Rangueil
Toulouse, France, 31400
Actively Recruiting
16
Centre Hospitalier de Valenciennes
Valenciennes, France, 59300
Actively Recruiting
17
Charite Universitaetsmedizin Berlin
Berlin, Germany, 10117
Actively Recruiting
18
Universitaetsklinikum Koeln (AoeR)
Cologne, Germany, 50931
Actively Recruiting
19
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany, 01307
Actively Recruiting
20
Universitaetsklinikum Essen
Essen, Germany, 45147
Actively Recruiting
21
Medizinische Hochschule Hannover (MHH)
Hanover, Germany, 30625
Actively Recruiting
22
Universitaetsklinikum Leipzig
Leipzig, Germany, 04103
Actively Recruiting
23
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Lübeck, Germany, 23562
Actively Recruiting
24
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Germany, 80802
Actively Recruiting
25
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, Italy, 24127
Actively Recruiting
26
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy, 50134
Actively Recruiting
27
IRCCS Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
28
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy, 00168
Actively Recruiting
29
APSS Ospedale Santa Chiara di Trento
Trento, Italy, 38122
Actively Recruiting
30
Fundacio Puigvert
Barcelona, Spain, 08025
Actively Recruiting
31
Hospital Universitari de Bellvitge
Barcelona, Spain, 08907
Actively Recruiting
32
Hospital Universitari Arnau de Vilanova
Lleida, Spain, 25198
Actively Recruiting
33
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
34
Hospital Regional Universitario de Malaga
Málaga, Spain, 29001
Actively Recruiting
35
Linkoping University Hospital
Linköping, Sweden, 581 85
Actively Recruiting
36
University Hospital of Umea
Umeå, Sweden, 907 37
Actively Recruiting
37
Kantonsspital Baden AG
Baden, Switzerland, 5404
Actively Recruiting
38
Inselspital, Universitaetsspital Bern
Bern, Switzerland, 3010
Actively Recruiting
39
Kantonsspital St. Gallen
Sankt Gallen, Switzerland, 9000
Actively Recruiting
40
Hôpital Fribourgeois-Freiburger Spital
Villars-sur-Glâne, Switzerland, 1752
Withdrawn
41
Ankara Etlik City Hospital
Ankara, Keçiören, Turkey (Türkiye)
Actively Recruiting
42
Marmara University Medical Faculty Hospital
Istanbul, Turkey (Türkiye)
Actively Recruiting
43
Kocaeli University Medical School - Internal Medicine - Nephrology
Kocaeli, Turkey (Türkiye)
Actively Recruiting
44
Erciyes University Faculty of Medicine
Melikgazi, Turkey (Türkiye)
Actively Recruiting
45
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom, B152GW
Actively Recruiting
46
Cambridge University - Addenbrooke's Hospital
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
47
Royal Liverpool University Hospital
Liverpool, United Kingdom, L78YE
Actively Recruiting
48
Imperial College Healthcare NHS Trust
London, United Kingdom, W21NY
Actively Recruiting
49
Royal Preston Hospital
Preston, United Kingdom, PR2 9HT
Actively Recruiting
Research Team
M
Mohamed Benabed
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here